These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 30348170)

  • 41. The value of harm reduction for injection drug use: A clinical and public health ethics analysis.
    Vearrier L
    Dis Mon; 2019 May; 65(5):119-141. PubMed ID: 30600096
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New York harm reduction educators.
    Ruefli T
    Newsline People AIDS Coalit N Y; 1998 Jun; ():9-12. PubMed ID: 11367473
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The 1st results in the realization of the Harm Reduction program for intravenous narcotic users in the city of Penza].
    Fedoseeva NS; Oleĭnik SV; Evdokimova MV
    Zh Mikrobiol Epidemiol Immunobiol; 2000; (4):85-7. PubMed ID: 10994118
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mapping violence and policing as an environmental-structural barrier to health service and syringe availability among substance-using women in street-level sex work.
    Shannon K; Rusch M; Shoveller J; Alexson D; Gibson K; Tyndall MW;
    Int J Drug Policy; 2008 Apr; 19(2):140-7. PubMed ID: 18207725
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Evaluation of a pilot study on needle and syringe exchange program among injecting drug users in a community in Guangdong, China].
    Lin P; Fan ZF; Yang F; Wu ZY; Wang Y; Liu YY; Ming ZQ; Li WJ; Luo W; Fu XB; Mai XR; Xu RH; Feng WY; He Q
    Zhonghua Yu Fang Yi Xue Za Zhi; 2004 Sep; 38(5):305-8. PubMed ID: 15498241
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Secondary syringe exchange as a model for HIV prevention programs in the Russian Federation.
    Irwin K; Karchevsky E; Heimer R; Badrieva L
    Subst Use Misuse; 2006; 41(6-7):979-99. PubMed ID: 16809182
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Benefits of concurrent syringe exchange and substance abuse treatment participation.
    Kidorf M; King VL; Peirce J; Kolodner K; Brooner RK
    J Subst Abuse Treat; 2011 Apr; 40(3):265-71. PubMed ID: 21255959
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Opioid Use Among Those Who Have Criminal Justice Experience: Harm Reduction Strategies to Lessen HIV Risk.
    Brinkley-Rubinstein L; Cloud D; Drucker E; Zaller N
    Curr HIV/AIDS Rep; 2018 Jun; 15(3):255-258. PubMed ID: 29752698
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Peer Recovery Specialists and Referrals to Treatment: Clinical Correlates Among Patients of an Opioid Overdose Recovery Program in New Jersey.
    Lardier DT; Gilmore-Powell K; Morton CM; Peterson NA; Borys S
    Subst Use Addctn J; 2024 Jul; 45(3):493-505. PubMed ID: 38469829
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The social logic of naloxone: Peer administration, harm reduction, and the transformation of social policy.
    Faulkner-Gurstein R
    Soc Sci Med; 2017 May; 180():20-27. PubMed ID: 28315595
    [TBL] [Abstract][Full Text] [Related]  

  • 51. No opiate substitutes for the masses of IDUs.
    Cohen J
    Science; 2010 Jul; 329(5988):165-7. PubMed ID: 20616264
    [No Abstract]   [Full Text] [Related]  

  • 52. Colocating Syringe Services, COVID-19 Vaccination, And Infectious Disease Testing: Baltimore's Experience.
    Heidari O; Meyer D; Lowensen K; Patil A; O'Conor KJ; LaRicci J; Hunt D; Bocek AP; Cargill V; Farley JE
    Health Aff (Millwood); 2024 Jun; 43(6):883-891. PubMed ID: 38830163
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Harm Reduction: Front Line Public Health.
    Stancliff S; Phillips BW; Maghsoudi N; Joseph H
    J Addict Dis; 2015; 34(2-3):206-19. PubMed ID: 26080038
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The rights of drug treatment patients: Experience of addiction treatment in Poland from a human rights perspective.
    Klingemann J
    Int J Drug Policy; 2017 May; 43():67-73. PubMed ID: 28231439
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of an enhanced needle and syringe programme: the First Step programme pilot.
    Hudoba M; Grenyer B; O'Toole M
    Drug Alcohol Rev; 2004 Sep; 23(3):295-7. PubMed ID: 15370009
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Positive Health Project.
    Farrell J
    Newsline People AIDS Coalit N Y; 1998 Jun; ():18-20. PubMed ID: 11367468
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improving substance abuse treatment enrollment in community syringe exchangers.
    Kidorf M; King VL; Neufeld K; Peirce J; Kolodner K; Brooner RK
    Addiction; 2009 May; 104(5):786-95. PubMed ID: 19413790
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 'I went for rehab many times and it never worked, but the harm reduction process has given me renewed hope'. Perceptions on the effectiveness of harm reduction and community-based opioid substitution therapy.
    Nyashanu T; Scheibe A; Visser M
    Health Promot J Austr; 2024 Jul; 35(3):653-661. PubMed ID: 37605794
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program.
    Kidorf M; Disney ER; King VL; Neufeld K; Beilenson PL; Brooner RK
    Drug Alcohol Depend; 2004 May; 74(2):115-22. PubMed ID: 15099655
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Harm Reduction for Adolescents and Young Adults During the COVID-19 Pandemic: A Case Study of Community Care in Reach.
    Noyes E; Yeo E; Yerton M; Plakas I; Keyes S; Obando A; Gaeta JM; Taveras EM; Chatterjee A
    Public Health Rep; 2021 May; 136(3):301-308. PubMed ID: 33673755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.